Coronavirus Vaccine ready by December

On Monday 9th of November early results from the world’s first effective coronavirus vaccine showed it could prevent more than 90% of people from getting Covid.

The Coronavirus vaccine has been developed by pharmaceutical companies Pfizer and BioNTech and is one of 11 vaccines that are currently in the final stages of testing.

The companies now plan to apply for emergency approval to use the vaccine as early as December.

The Uk has already ordered 40 million Vaccines and plan to vaccinate 1 million people per week, which means it could take a year to vaccinate the whole Population. The Vaccine for Covid-19 must be must be stored at -70C (-94F) and there is a 15 minute wait after each vaccination.

The British Medical Association, which represents doctors, said GPs have been told to prepare to give patients two vaccine doses – to be delivered between 21 and 28 days apart – during clinics that could run between 08:00 and 20:00 GMT seven days a week.

It added that, due to the logistics and delivery requirements, including the need to store it at very cold temperatures, it was likely that groups of GP practices would need to work together with one “designated vaccination site”.

Matt Hancock said “If regulators are able to give the green light in the next few weeks, some people could get their jab before Christmas – a most welcome gift for those at highest risk of severe Covid-19 illness”.
But he doesn’t want people to get their hopes up too soon or assume life can now return to “normal”. It can’t.
It would be a colossal mistake to relax now and let the virus rip, say leading medical advisers.
Until and unless mass vaccination can happen, society needs to use the other weapons at its disposal to fight the virus and stop the spread.
That means sticking with the social distancing and face masks, and testing people who may have the virus and asking them to isolate.

Statement from Pfizer:

Monday, November 09, 2020 – 06:45am

  • Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
  • Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
  • Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
  • Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
  • Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints

error: Content is protected !!